Deep Medicine Acquisition - Tradeable Rights - Oct 2026 Receivables

As of the most recent data (March 2026), DMAQR shows a receivables of $1.3M. That compares with $1.6M in the prior-year period — down 16.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DMAQR's receivables is now $1.3M (was $1.6M) — a 16.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Deep Medicine Acquisition - Tradeable Rights - Oct 2026 is outperforming or lagging.

Tracking DMAQR's receivables over time shows whether Deep Medicine Acquisition - Tradeable Rights - Oct 2026 is scaling, shrinking, or reshaping that part of the business. The current reading is $1.3M That compares with $1.6M in the prior-year period — down 16.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Deep Medicine Acquisition - Tradeable Rights - Oct 2026's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $1.3M) with ownership activity and broader fundamentals.